Human Genome Epidemiology Literature Finder
|
Records 1 - 13 (of 13 Records) |
| Query Trace: Colorectal Neoplasms and FCGR3A[original query] |
|---|
| FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Aug 25 (24): 3712-8. Zhang Wu, Gordon Michael, Schultheis Anne M, Yang Dong Yun, Nagashima Fumio, Azuma Mizutomo, Chang Heung-Moon, Borucka Eva, Lurje Georg, Sherrod Andy E, Iqbal Syma, Groshen Susan, Lenz Heinz-Jos |
| Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. European journal of cancer (Oxford, England : 1990) 2010 Jul 46 (10): 1829-34. Pander Jan, Gelderblom Hans, Antonini Ninja F, Tol Jolien, van Krieken Johan H J M, van der Straaten Tahar, Punt Cornelis J A, Guchelaar Henk-J |
| Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer research 2010 Oct 30 (10): 4209-17. Zhang Wu, Azuma Mizutomo, Lurje Georg, Gordon Michael A, Yang Dongyun, Pohl Alexandra, Ning Yan, Bohanes Pierre, Gerger Armin, Winder Thomas, Hollywood Ellen, Danenberg Kathleen D, Saltz Leonard, Lenz Heinz-Jos |
| Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer 2011 Nov 11 (1): 1. Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, Gaudart J, Garcia S, Ouafik L, Seitz JF, Milano G |
| Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. British journal of clinical pharmacology 2012 May 73 (5): 776-85. Etienne-Grimaldi Marie-Christine, Bennouna Jaafar, Formento Jean-Louis, Douillard Jean-Yves, Francoual Mireille, Hennebelle Isabelle, Chatelut Etienne, Francois Eric, Faroux Roger, El Hannani Chaza, Jacob Jacques-Henri, Milano Géra |
| FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut 2015 Jun 64 (6): 921-8. Geva Ravit, Vecchione Loredana, Kalogeras Konstantinos T, Jensen Benny Vittrup, Lenz Heinz-Josef, Yoshino Takayuki, Paez David, Montagut Clara, Souglakos John, Cappuzzo Federico, Cervantes Andrés, Frattini Milo, Fountzilas George, Johansen Julia S, Høgdall Estrid Vilma, Zhang Wu, Yang Dongyun, Yamazaki Kentaro, Nishina Tomohiro, Papamichael Demetris, Vincenzi Bruno, Macarulla Teresa, Loupakis Fotios, De Schutter Jef, Spindler Karen Lise Garm, Pfeiffer Per, Ciardiello Fortunato, Piessevaux Hubert, Tejpar Sabi |
| FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC cancer 2014 14 (1): 340. Kjersem Janne B, Skovlund Eva, Ikdahl Tone, Guren Tormod, Kersten Christian, Dalsgaard Astrid M, Yilmaz Mette K, Fokstuen Tone, Tveit Kjell M, Kure Elin |
| FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer. Oncotarget 2015 Aug . Ying Hou-Qun, Wang Feng, Chen Xiao-Lin, He Bang-Shun, Pan Yu-Qin, Jie Chen, Liu Xian, Cao Wei-Jun, Peng Hong-Xin, Lin Kang, Wang Shu-K |
| Fc-? Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 May 22 (10): 2435-44. Liu Geoffrey, Tu Dongsheng, Lewis Marcia, Cheng Dangxiao, Sullivan Leslie A, Chen Zhuo, Morgen Eric, Simes John, Price Timothy J, Tebbutt Niall C, Shapiro Jeremy D, Jeffery G Mark, Mellor J Daniel, Mikeska Thomas, Virk Shakeel, Shepherd Lois E, Jonker Derek J, O'Callaghan Christopher J, Zalcberg John R, Karapetis Christos S, Dobrovic Alexand |
| Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. World journal of gastrointestinal oncology 2016 Feb 8 (2): 222-30. Lo Nigro Cristiana, Ricci Vincenzo, Vivenza Daniela, Monteverde Martino, Strola Giuliana, Lucio Francesco, Tonissi Federica, Miraglio Emanuela, Granetto Cristina, Fortunato Mirella, Merlano Marco Car |
| Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. The pharmacogenomics journal 2016 Nov . Morgen E K, Lenz H-J, Jonker D J, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis C S, Dobrovic A, O'Callaghan C J, Liu |
| The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. The pharmacogenomics journal 2017 Jul . Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle |
| Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer medicine 2018 Oct . Shepshelovich Daniel, Townsend Amanda R, Espin-Garcia Osvaldo, Latifovic Lidija, O'Callaghan Chris J, Jonker Derek J, Tu Dongsheng, Chen Eric, Morgen Eric, Price Timothy J, Shapiro Jeremy, Siu Lillian L, Kubo Michiaki, Dobrovic Alexander, Ratain Mark J, Xu Wei, Mushiroda Taisei, Liu Geoffr |
- Page last reviewed:Feb 1, 2023
- Page last updated:Jun 02, 2023
- Content source: